An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (Imbrella B)
MD Anderson Study Status
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
David Sanghyun Hong
Investigational Cancer Therapeutics
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.